Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROCKEFELLER UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Persistent Innate Immune Activation on Vaccine Efficacy

Phase 4

Terminated

Conditions: Hepatitis C Infection

Interventions: Drug: Recombivax

First Posted Date: 2015-04-29

Last Posted Date: 2020-03-04

Lead Sponsor: Rockefeller University

Target Recruit Count: 24

Registration Number: NCT02429583

Locations: 🇺🇸
Rockefeller University Hospital, New York, New York, United States

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

Phase 4

Completed

Conditions: Hepatitis C

Interventions: Drug: Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

First Posted Date: 2015-01-27

Last Posted Date: 2019-08-13

Lead Sponsor: Rockefeller University

Target Recruit Count: 34

Registration Number: NCT02347345

Locations: 🇺🇸
Rockefeller University Hospital, New York, New York, United States

A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin

Not Applicable

Completed

Conditions: Skin Disease

Interventions: Drug: Petrolatum application under occlusion

First Posted Date: 2015-01-14

Last Posted Date: 2017-05-16

Lead Sponsor: Rockefeller University

Target Recruit Count: 20

Registration Number: NCT02338076

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

Not Applicable

Completed

Conditions: Hepatitis B

Interventions: Biological: Hepatitis B Vaccine (Recombinant)

First Posted Date: 2014-02-05

Last Posted Date: 2018-05-07

Lead Sponsor: Rockefeller University

Target Recruit Count: 10

Registration Number: NCT02055365

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Discovering the Antecedents of Rheumatoid Arthritis Flare

Active, not recruiting

Conditions: Rheumatoid Arthritis

First Posted Date: 2014-01-31

Last Posted Date: 2025-03-27

Lead Sponsor: Rockefeller University

Target Recruit Count: 25

Registration Number: NCT02051114

Locations: 🇺🇸
The Rockefeller University Hospital, New York, New York, United States

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

Phase 1

Completed

Conditions: Healthy
HIV

Interventions: Biological: 3 mg/kg, single dose IV administration of 3BNC117
Biological: 10 mg/kg, two doses IV of 3BNC117
Biological: 1 mg/kg, single dose IV administration of 3BNC117
Biological: 30 mg/kg, single dose IV administration of 3BNC117
Biological: 30 mg/kg, two doses IV of 3BNC117
Biological: 10 mg/kg, single dose IV administration of 3BNC117

First Posted Date: 2013-12-23

Last Posted Date: 2016-12-26

Lead Sponsor: Rockefeller University

Target Recruit Count: 49

Registration Number: NCT02018510

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
The Rockefeller University, New York, New York, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States

and more 1 locations

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

Not Applicable

Conditions: Healthy

Interventions: Biological: IM Pneumococcal, meningococcal, or flu vaccine

First Posted Date: 2013-10-22

Last Posted Date: 2022-06-02

Lead Sponsor: Rockefeller University

Target Recruit Count: 140

Registration Number: NCT01967238

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: ILV-094
Drug: Placebo Comparator

First Posted Date: 2013-09-13

Last Posted Date: 2019-05-07

Lead Sponsor: Rockefeller University

Target Recruit Count: 60

Registration Number: NCT01941537

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Comparative Analysis of Small and Large Plaque Psoriasis

Not Applicable

Completed

Conditions: Psoriasis

Interventions: Procedure: Skin biopsy and blood test

First Posted Date: 2013-08-12

Last Posted Date: 2016-05-06

Lead Sponsor: Rockefeller University

Target Recruit Count: 13

Registration Number: NCT01920906

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

Early Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Celebrex

First Posted Date: 2013-07-17

Last Posted Date: 2021-02-01

Lead Sponsor: Rockefeller University

Target Recruit Count: 10

Registration Number: NCT01901679

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy